Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clobazam: single or divided doses?

C Arnau, J M Costa Molinari, C Piña

    European Journal of Clinical Pharmacology
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The von Willebrand factor/ADAMTS13 ratio as an indicator of venous thromboembolism risk: results from the RETROVE project.

    Journal of thrombosis and thrombolysis·2025
    Same author

    Low ADAMTS13 levels are associated with venous thrombosis risk in women.

    Thrombosis research·2017
    Same author

    An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Effectiveness of two intracanal dressings in adult Portuguese patients: a qPCR and anaerobic culture assessment.

    International endodontic journal·2013
    Same author

    Evaluation and insights into chitosan antimicrobial activity against anaerobic oral pathogens.

    Anaerobe·2012
    Same author

    Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators.

    Oncogene·2007
    Same journal

    Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

    European journal of clinical pharmacology·2026
    Same journal

    Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

    European journal of clinical pharmacology·2026
    Same journal

    The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

    European journal of clinical pharmacology·2026
    Same journal

    Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

    European journal of clinical pharmacology·2026
    Same journal

    Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

    European journal of clinical pharmacology·2026
    Same journal

    Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

    European journal of clinical pharmacology·2026
    See all related articles

    Clobazam effectively treats neurotic disorders, with single or divided daily doses showing similar results in managing anxiety and sleep issues. This anxiolytic drug is a useful option for patients.

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Clinical Trials

    Background:

    • Neurotic disorders present significant challenges in anxiety management.
    • Clobazam is an anxiolytic drug used for treating anxiety disorders.
    • Understanding optimal dosing strategies is crucial for effective treatment.

    Purpose of the Study:

    • To compare the efficacy of single versus divided daily doses of clobazam in treating neurotic disorders.
    • To evaluate the impact of different clobazam dosing schedules on anxiety symptoms and sleep disturbances.
    • To assess the overall clinical impression and tolerance of clobazam across different dosing regimens.

    Main Methods:

    • A randomized subgroup of 114 patients from a larger postmarketing surveillance trial was analyzed.

    Related Experiment Videos

  • Patients were divided into two groups of 57, matched for age, sex, diagnosis, and initial disorder severity.
  • The study compared treatment outcomes between single and divided daily doses of clobazam.

    • Main Results:

    • Both single and divided daily doses of clobazam demonstrated comparable efficacy in treating neurotic disorders.
    • Significant improvements were observed in overall symptom severity, persistent anxiety, anxiety crises, and sleep disorders.
    • Global clinical impression and drug tolerance were similar between the two dosing schedules.

    Conclusions:

    • Clobazam is confirmed as a useful anxiolytic medication for neurotic disorders.
    • Single and divided daily dosage regimens of clobazam yield similar therapeutic results.
    • The findings support the flexibility in prescribing clobazam dosing schedules based on patient needs and response.